A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.
The three-pronged regimen of Velcade, lenalidomide (Revlimid) and dexamethasone - referred to as [...]